Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Shinichi Goto; Shinya Goto

doi:10.1161/circulationaha.115.015471

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Circulation ◽

10.1161/circulationaha.115.015471 ◽

2015 ◽

Vol 131 (12) ◽

pp. 1041-1043 ◽

Cited By ~ 7

Author(s):

Shinichi Goto ◽

Shinya Goto

Keyword(s):

Myocardial Infarction ◽

Clinical Trial ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Patient Population ◽

Thrombin Receptor ◽

Large Clinical Trial ◽

Ischemic Events ◽

Thrombin Receptor Antagonist ◽

Selection Of

Download Full-text

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

Journal of the American Heart Association ◽

10.1161/jaha.116.003237 ◽

2016 ◽

Vol 5 (7) ◽

Cited By ~ 10

Author(s):

Stephen K. Kidd ◽

Marc P. Bonaca ◽

Eugene Braunwald ◽

Gaetano M. De Ferrari ◽

Basil S. Lewis ◽

...

Keyword(s):

Myocardial Infarction ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Classification System ◽

Thrombin Receptor ◽

System Type ◽

Ischemic Events ◽

Thrombin Receptor Antagonist

Download Full-text

VORAPAXAR AND ACUTE LIMB ISCHEMIA: INSIGHTS FROM THE THROMBIN RECEPTOR ANTAGONIST IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC ISCHEMIC EVENTS-TIMI 50 TRIAL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(15)62047-2 ◽

2015 ◽

Vol 65 (10) ◽

pp. A2047 ◽

Cited By ~ 1

Author(s):

Antonio Gutierrez ◽

Marc Bonaca ◽

Benjamin Scirica ◽

Mark Creager ◽

Sabina Murphy ◽

...

Keyword(s):

Secondary Prevention ◽

Receptor Antagonist ◽

Limb Ischemia ◽

Thrombin Receptor ◽

Acute Limb Ischemia ◽

Ischemic Events ◽

Thrombin Receptor Antagonist

Download Full-text

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

American Heart Journal ◽

10.1016/j.ahj.2009.06.027 ◽

2009 ◽

Vol 158 (3) ◽

pp. 335-341.e3 ◽

Cited By ~ 131

Author(s):

David A. Morrow ◽

Benjamin M. Scirica ◽

Keith A.A. Fox ◽

Gail Berman ◽

John Strony ◽

...

Keyword(s):

Secondary Prevention ◽

Receptor Antagonist ◽

Antiplatelet Agent ◽

Atherosclerotic Disease ◽

Thrombin Receptor ◽

History Of ◽

Ischemic Events ◽

Thrombin Receptor Antagonist

Download Full-text

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial

European Heart Journal ◽

10.1093/eurheartj/eht104 ◽

2013 ◽

Vol 34 (23) ◽

pp. 1723-1731 ◽

Cited By ~ 25

Author(s):

S. Leonardi ◽

P. Tricoci ◽

H. D. White ◽

P. W. Armstrong ◽

Z. Huang ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(16)30457-0 ◽

2016 ◽

Vol 67 (13) ◽

pp. 456

Author(s):

Francesco Costa ◽

Marco Valgimigli ◽

Yuliya Lokhnygina ◽

Robert Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

American Heart Journal ◽

10.1016/j.ahj.2017.10.007 ◽

2018 ◽

Vol 196 ◽

pp. 28-35 ◽

Cited By ~ 5

Author(s):

Patrícia O. Guimarães ◽

Sergio Leonardi ◽

Zhen Huang ◽

Lars Wallentin ◽

Frans Van de Werf ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Features ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

Faculty Opinions recommendation of Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717992295.793487025 ◽

2013 ◽

Author(s):

Venu Menon ◽

Bhuvnesh Aggarwal

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

European Heart Journal ◽

10.1093/eurheartj/ehw525 ◽

2016 ◽

pp. ehw525 ◽

Cited By ~ 16

Author(s):

Marco Valgimigli ◽

Francesco Costa ◽

Yuliya Lokhnygina ◽

Robert M. Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Trade Off ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

The Role of Exploratory Drug Metabolism and Pharmacokinetics in New Drug Research: Case Study-Selection of a Thrombin Receptor Antagonist for Development

Current Pharmaceutical Design ◽

10.2174/138161209788682497 ◽

2009 ◽

Vol 15 (19) ◽

pp. 2262-2269 ◽

Cited By ~ 3

Author(s):

Yunsheng Hsieh ◽

K.-C. Cheng ◽

Yuguang Wang ◽

Samuel Chackalamannil ◽

Yan Xia ◽

...

Keyword(s):

Drug Metabolism ◽

Receptor Antagonist ◽

Drug Research ◽

Thrombin Receptor ◽

New Drug ◽

Study Selection ◽

Thrombin Receptor Antagonist ◽

Selection Of

Download Full-text

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2015.02.043 ◽

2015 ◽

Vol 115 (10) ◽

pp. 1325-1332 ◽

Cited By ~ 11

Author(s):

Jan H. Cornel ◽

Pierluigi Tricoci ◽

Yuliya Lokhnygina ◽

David J. Moliterno ◽

Lars Wallentin ◽

...

Keyword(s):

Receptor Antagonist ◽

Acute Coronary Syndromes ◽

Thrombin Receptor ◽

St Segment Elevation ◽

St Segment ◽

Coronary Syndromes ◽

Thrombin Receptor Antagonist

Download Full-text